Northcoast Research set a $102.00 target price on Steris (NYSE:STE) in a research note released on Thursday. The firm currently has a buy rating on the medical equipment provider’s stock. Northcoast Research also issued estimates for Steris’ Q4 2018 earnings at $1.22 EPS, FY2018 earnings at $4.13 EPS, Q1 2019 earnings at $0.99 EPS, Q2 2019 earnings at $1.12 EPS, Q4 2019 earnings at $1.39 EPS and FY2019 earnings at $4.77 EPS.
Several other equities research analysts have also recently issued reports on STE. Raymond James Financial lifted their price objective on Steris from $95.00 to $100.00 and gave the stock an outperform rating in a report on Monday, October 16th. KeyCorp reiterated a buy rating and issued a $91.00 price objective on shares of Steris in a report on Tuesday, October 17th. Zacks Investment Research cut Steris from a buy rating to a sell rating in a report on Monday, November 6th. Finally, TD Securities lifted their price objective on Steris from C$14.00 to C$16.00 and gave the stock a buy rating in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Steris presently has an average rating of Buy and an average target price of $84.80.
Steris (STE) opened at $85.57 on Thursday. The company has a quick ratio of 2.18, a current ratio of 2.82 and a debt-to-equity ratio of 0.46. Steris has a 52 week low of $66.84 and a 52 week high of $93.71. The firm has a market capitalization of $7,290.00, a PE ratio of 30.13 and a beta of 1.22.
Steris (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.05. Steris had a return on equity of 11.57% and a net margin of 9.42%. The company had revenue of $661.90 million for the quarter, compared to analysts’ expectations of $663.17 million. During the same period in the previous year, the firm posted $0.98 EPS. Steris’s revenue was up 2.3% compared to the same quarter last year. research analysts forecast that Steris will post 4.13 earnings per share for the current year.
In related news, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Sudhir K. Pahwa sold 2,000 shares of Steris stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $92.09, for a total value of $184,180.00. The disclosure for this sale can be found here. Insiders own 2.55% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Steris by 1.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 25,416 shares of the medical equipment provider’s stock worth $2,071,000 after purchasing an additional 379 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Steris by 5.9% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 9,817 shares of the medical equipment provider’s stock worth $859,000 after purchasing an additional 547 shares during the last quarter. Comerica Bank boosted its holdings in shares of Steris by 0.9% during the 4th quarter. Comerica Bank now owns 68,219 shares of the medical equipment provider’s stock worth $6,255,000 after purchasing an additional 628 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Steris by 6.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 9,810 shares of the medical equipment provider’s stock worth $858,000 after purchasing an additional 630 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Steris by 0.6% during the 3rd quarter. Swiss National Bank now owns 142,255 shares of the medical equipment provider’s stock worth $12,575,000 after purchasing an additional 800 shares during the last quarter. Institutional investors and hedge funds own 89.63% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Northcoast Research Reiterates “$102.00” Price Target for Steris (STE)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/02/12/northcoast-research-reiterates-102-00-price-target-for-steris-ste.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.